Document is current

Article History

Received: 25 January 2024

Accepted: 15 April 2024

First Online: 29 May 2024

Declarations

:

: The study was performed following Good Pharmacoepidemiology Practice. All participating investigators were required to obtain full board approval for conducting noninterventional research involving human subjects with a limited dataset. Sponsor approval and continuing review was obtained through a central Institutional Review Board (IRB), the New England Independent Review Board (NEIRB; no. 120160610). For academic investigative sites that did not receive a waiver to use the central IRB, full board approval was obtained from the respective governing IRBs and documentation of approval was submitted to CorEvitas, LLC prior to the initiation of any study procedures. All patients in the registry were required to provide written informed consent and authorization prior to participating.

: Jud C. Janak accepts full responsibility for the conduct of the study and has access to the data and control of the decision to publish.

: JCJ, CAL, AML: Former Employee of CorEvitas, LLC; PCM: Employee of CorEvitas, LLC; PJM: (Grant Research) AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Inc., Sun, UCB; (Consulting) AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, Inc., Sun Pharma, and UCB; (Speakers Bureau) AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Inc., and UCB; ML: Employee of Mount Sinai and receives research funds from: AbbVie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Janssen Research & Development, LLC, Ortho Dermatologics, Regeneron, and UCB, Inc., and is a consultant for Aditum Bio, Almirall, AltruBio Inc., AnaptysBio, Arcutis, Inc., Arena Pharmaceuticals, Aristea Therapeutics, Arrive Technologies, Avotres Therapeutics, BiomX, Brickell Biotech, Boehringer-Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, CorEvitas, Dermavant Sciences, Dr. Reddy’s Laboratories, Evelo Biosciences, Evommune, Inc., Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Helsinn Therapeutics, Hexima Ltd., LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Seanergy, and Verrica; JRK: Research Support: AbbVie, Pfizer, Inc.; Consultant: Genentech, Thetis; Founder: ColonaryConcepts; RKC: Consulting and/or Participation in Advisory Boards for AbbVie, Bristol Myers Squibb, Eli Lilly, Fzata, LabCorp, Magellan Health, Janssen, Pfizer, Samsung Bioepis, Takeda; DH: Consultant for AbbVie, Bristol Myers Squibb, Janssen, Pfizer, Inc., Takeda, and UCB.